Compare IDEXX Laboratories, Inc. (IDXX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs NEOS S&P 500 High Income ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.2× NEOS S&P 500 High Income ETF's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and NEOS S&P 500 High Income ETF for 58 Days on average.
| IDXX | SPYI | |
|---|---|---|
Market Cap | $40.43B | $12.50B |
Volume | 692,164 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $54.42 |
52-Week Low | $504.70 | $47.98 |
Typical Hold Time | 46 Days | 58 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
SPYI trades at $53.86, down 0.28% with a bullish technical signal from moving averages but neutral oscillators. The ETF shows strong income focus with recent monthly dividends around $0.53-0.54, though financial ratios remain undisclosed. Recent news highlights SPYI's popularity for high-yield strategies while raising concerns about principal erosion from covered call strategies.
Outlook remains mixed with technical strength offset by fundamental questions about long-term capital preservation. The ETF appeals to income-seeking investors but faces sequence risk in retirement portfolios. Key risks include covered call limitations during bull markets and sensitivity to market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
